Acupuncture for Prediabetes With Combined Obesity

NCT06359418 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2025-08-22

No results posted yet for this study

Summary

The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.

Conditions

Interventions

DEVICE

Acupuncture

The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).

DEVICE

Sham acupuncture

The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.

Sponsors & Collaborators

  • Hubei Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Guangdong Provincial Hospital of Chinese Medicine, Zhuhai

    collaborator UNKNOWN
  • The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

    collaborator OTHER
  • Dongfang Hospital Beijing University of Chinese Medicine

    collaborator OTHER
  • Linyi Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Xi'an Traditional Chinese Medicine Hospital

    collaborator OTHER
  • Qingdao Traditional Chinese Medicine Hospital

    collaborator UNKNOWN
  • Xi'an Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Heilongjiang Academy of traditional Chinese Medicine

    collaborator UNKNOWN
  • The Affiliated Hospital of Qingdao University

    collaborator OTHER
  • Yantai Hospital of Traditional Chinese Medicine

    collaborator UNKNOWN
  • Shaanxi Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Zhishun Liu, PhD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2027-06-01
Completion
2028-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359418 on ClinicalTrials.gov